Company registration number 13242952 (England and Wales)
MOSAIC BIOPHARMA CONSULTING LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
PAGES FOR FILING WITH REGISTRAR
MOSAIC BIOPHARMA CONSULTING LTD
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2
MOSAIC BIOPHARMA CONSULTING LTD
BALANCE SHEET
AS AT 31 MARCH 2025
31 March 2025
- 1 -
2025
2024
Notes
£
£
£
£
Current assets
Cash at bank and in hand
45,411
55,797
Creditors: amounts falling due within one year
3
(13,372)
(12,353)
Net current assets
32,039
43,444
Capital and reserves
Called up share capital
2
2
Profit and loss reserves
32,037
43,442
Total equity
32,039
43,444

For the financial year ended 31 March 2025 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 10 December 2025 and are signed on its behalf by:
Mr F Weston
Director
Company registration number 13242952 (England and Wales)
MOSAIC BIOPHARMA CONSULTING LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
- 2 -
1
Accounting policies
Company information

Mosaic Biopharma Consulting Ltd is a private company limited by shares incorporated in England and Wales. The registered office is 22 Friars Street, Sudbury, Suffolk, CO10 2AA.

1.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.3
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
2
2
3
Creditors: amounts falling due within one year
2025
2024
£
£
Other creditors
13,372
12,353
2025-03-312024-04-01falsefalsetrue12 December 2025CCH SoftwareCCH Accounts Production 2025.300No description of principal activityMr F WestonMr David Weston132429522024-04-012025-03-31132429522025-03-31132429522024-03-3113242952core:CurrentFinancialInstruments2025-03-3113242952core:CurrentFinancialInstruments2024-03-3113242952core:ShareCapital2025-03-3113242952core:ShareCapital2024-03-3113242952core:RetainedEarningsAccumulatedLosses2025-03-3113242952core:RetainedEarningsAccumulatedLosses2024-03-3113242952bus:Director12024-04-012025-03-31132429522023-04-012024-03-3113242952bus:EntityNoLongerTradingButTradedInPast2024-04-012025-03-3113242952bus:PrivateLimitedCompanyLtd2024-04-012025-03-3113242952bus:SmallCompaniesRegimeForAccounts2024-04-012025-03-3113242952bus:FRS1022024-04-012025-03-3113242952bus:AuditExemptWithAccountantsReport2024-04-012025-03-3113242952bus:Director22024-04-012025-03-3113242952bus:FullAccounts2024-04-012025-03-31xbrli:purexbrli:sharesiso4217:GBP